B. Metzler seel. Sohn & Co. Holding AG Makes New $4.67 Million Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the third quarter, Holdings Channel.com reports. The fund bought 9,235 shares of the company’s stock, valued at approximately $4,666,000.

Several other hedge funds and other institutional investors also recently modified their holdings of IDXX. American Century Companies Inc. grew its holdings in shares of IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock worth $274,179,000 after acquiring an additional 177,226 shares during the period. International Assets Investment Management LLC boosted its position in shares of IDEXX Laboratories by 52,746.0% during the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock valued at $2,669,890,000 after purchasing an additional 527,460 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in IDEXX Laboratories by 13.1% in the second quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company’s stock worth $249,855,000 after purchasing an additional 59,519 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in IDEXX Laboratories by 12.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 390,565 shares of the company’s stock worth $190,283,000 after purchasing an additional 43,473 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its position in IDEXX Laboratories by 696.0% during the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company’s stock valued at $171,891,000 after buying an additional 308,493 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.8 %

IDXX opened at $416.34 on Wednesday. IDEXX Laboratories, Inc. has a twelve month low of $404.74 and a twelve month high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average price of $465.52 and a 200-day moving average price of $481.99. The stock has a market capitalization of $34.09 billion, a price-to-earnings ratio of 40.15, a PEG ratio of 3.67 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.53 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

IDXX has been the topic of several research reports. Piper Sandler restated a “neutral” rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. JPMorgan Chase & Co. lowered their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Barclays decreased their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Finally, BTIG Research began coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $552.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.